GLP-1 Medications and Eating Disorders: Current Evidence and Risks
Author: Angela Bogdanova · Published: October 10, 2026 · Editorial Policy
Research cluster: Eating Disorders & Disordered Eating · Written by Artificial Sapiens
GLP-1 medications are changing the treatment of type 2 diabetes and obesity. Their effects on appetite, fullness, and food-related thoughts also create important questions for people living with, recovering from, or at risk of eating disorders. Some studies suggest reductions in binge-eating symptoms. At the same time, appetite suppression and gastrointestinal effects may complicate nutritional rehabilitation or reinforce restrictive patterns in vulnerable people.
The evidence as of October 2026 supports careful, individualized medical assessment rather than a general conclusion that GLP-1 medicines treat or cause eating disorders. They have not been established as treatments for anorexia nervosa, bulimia nervosa, or binge eating disorder. Most findings about reduced binge eating have come from obesity and diabetes trials rather than large studies recruiting people with a confirmed psychiatric eating-disorder diagnosis.
A 2026 systematic review and meta-analysis identified modest average reductions in binge-eating measures across randomized trials, along with increased measured dietary restraint. An independent September 2026 multidisciplinary expert consensus recommended screening for current and past eating disorders before prescribing, continued monitoring, and generally avoiding these medications in certain active restrictive disorders. The distinction between promising evidence, unresolved risk, and established treatment is central to responsible care.
What Are GLP-1 Medications?
Glucagon-like peptide-1 (GLP-1) is a hormone involved in glucose regulation, appetite, and gastrointestinal physiology. GLP-1 receptor agonists mimic some of its effects, increasing glucose-dependent insulin secretion, altering glucagon signaling, slowing gastric emptying to different degrees, and influencing brain pathways involved in hunger and satiety. Depending on the exact product, these medicines may be approved for type 2 diabetes, chronic weight management, or other specific cardiometabolic indications. The World Health Organization provides a useful explanation of their role.
Semaglutide, liraglutide, and dulaglutide belong to the GLP-1 receptor agonist class. Tirzepatide is often discussed in the same conversation but acts on both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, making it a dual incretin agonist. Ozempic, Wegovy, Rybelsus, Saxenda, Mounjaro, and Zepbound are product names with differing formulations, approved uses, and prescribing information. Approval for metabolic care is distinct from approval for treating a psychiatric eating disorder.
Many patients report a change in their experience of hunger, interest in food, or persistent thoughts about eating. Some describe this as quieter “food noise.” The expression describes a subjective experience, not a recognized diagnostic criterion. Researchers need validated measures to determine which aspects of food-related thinking change, which are clinically beneficial, and whether changes persist after medication is stopped.
Why GLP-1 Medications Matter in Eating Disorders
An eating disorder is diagnosed by clinically significant patterns of eating behavior, psychological features, impairment, and sometimes serious medical consequences. These conditions include restriction, binge eating, compensatory behavior, sensory or fear-based food avoidance, and other distinct presentations. The National Institute of Mental Health describes major diagnostic categories and emphasizes their seriousness across body sizes.
A medication-induced reduction in appetite is not itself an eating-disorder diagnosis. A lower body weight is not proof that an eating disorder has improved. Conversely, a person can experience profound malnutrition or medical instability at a weight that appears typical or elevated. Assessment must connect behavioral, psychological, nutritional, and medical information.
The same pharmacological effect can have different significance depending on the patient. Reduced urgency to eat might feel helpful to someone experiencing recurrent loss-of-control eating. In a person recovering from restrictive anorexia, a similar reduction could make nutritional restoration more difficult. In a person with diabetes and a past eating disorder, treatment decisions may require balancing legitimate metabolic benefits with psychological vulnerability.
This makes GLP-1 use an intersection of two clinical domains. The drug's metabolic indication must be assessed according to appropriate medical guidance, while eating-disorder symptoms require their own diagnostic and treatment framework. Neither should be inferred from the other.
What the Current Research Shows
The 2026 meta-analysis of randomized trials
The eClinicalMedicine meta-analysis by Emptage and colleagues included 25 randomized trials and 8,069 participants. Across nine trials contributing to the binge-eating outcome, GLP-1 receptor agonists were associated with a reduction in binge-eating measures compared with controls, with Hedges' g = −0.23. Other measured domains included loss-of-control eating, disinhibition, and emotional eating.
The authors also identified increased cognitive or dietary restraint, with a pooled standardized effect of g = 0.31. Restraint is not a single clinical phenomenon. A questionnaire may capture intentional eating regulation, rigid rules, or patterns that acquire different meanings depending on the person's symptoms and context. The pooled result does not establish that every increase in restraint was either healthy or harmful.
Every included trial was judged to have high risk of bias or some bias concerns, and heterogeneity was substantial. Most participants were recruited for obesity or related medical conditions rather than confirmed eating disorders. Consequently, improvement on a scale measuring binge-related behavior in an obesity trial should not be reported as proof of remission from DSM-5-TR binge eating disorder. The authors called for adequately powered, longer trials involving clinically diagnosed populations.
The rapid review of eating behavior and eating-disorder risk
Jebeile and colleagues' rapid review, released online in December 2025 and published in the 2026 volume of Obesity Reviews, synthesized 25 studies involving adults and adolescents treated for obesity or type 2 diabetes. Some studies reported improvements in binge-eating-related measures and cravings; other outcomes remained unchanged. Information about new or worsening diagnosed eating disorders was limited.
This limitation matters because large metabolic trials often measure weight, glucose control, and common adverse effects in greater detail than eating-disorder psychopathology. If a trial lacks a systematic psychiatric interview and follow-up designed to detect emerging restrictive illness, the absence of documented eating-disorder cases cannot determine whether the risk is zero.
The randomized liraglutide pilot trial
A 17-week randomized pilot trial enrolled 27 adults with binge eating disorder to receive liraglutide or placebo. Both groups showed reductions in objective binge episodes, but the between-group difference was not statistically significant. Remission proportions also did not significantly differ, while body-weight change was greater in the liraglutide group. A pharmacy-dispensing error further limited interpretation.
This study is particularly relevant because participants actually had binge eating disorder. Its size and duration, however, were insufficient to establish clinical efficacy. It also demonstrates why a reduction in body weight and a reduction in eating-disorder symptoms must be treated as separate outcomes.
Observational findings involving semaglutide
A 2023 retrospective cohort study reported improvements in Binge Eating Scale scores among people receiving semaglutide. Its nonrandomized design leaves important possibilities for confounding, including baseline differences, treatment selection, accompanying care, and the use of a questionnaire rather than independently confirmed diagnostic remission. The result is useful for generating hypotheses and designing more rigorous studies.
The September 2026 clinical consensus
A modified Delphi study in World Psychiatry convened 45 clinicians, researchers, and people with lived experience of eating disorders or GLP-1 treatment. It recommended assessing current and past eating-disorder symptoms, using brief validated screening instruments when appropriate, providing education, and monitoring symptoms during and after treatment. For patients with diagnosed eating disorders using these medications, panelists supported access to concurrent evidence-based psychotherapy.
The panel recommended generally avoiding GLP-1 drugs in active anorexia nervosa, atypical anorexia nervosa, and bulimia nervosa accompanied by marked dietary restraint or significant weight suppression. The authors emphasized individualized clinical judgment rather than treating every possible eating-disorder history as an identical or absolute contraindication.
Consensus recommendations help clinicians act responsibly where direct trial evidence is insufficient. They are not the same as randomized evidence that a proposed monitoring schedule prevents adverse outcomes. The recommendations will need to evolve with new clinical trials and epidemiological evidence.
Can GLP-1 Medications Treat Binge Eating Disorder?
Binge eating disorder (BED) involves recurrent episodes of loss-of-control eating and clinically significant distress. It differs from occasional overeating, high appetite, and obesity. Improving BED means addressing episodes, distress, impairing behavior, emotional functioning, and the maintenance of recovery. Changes in the number on a scale or the bathroom scale are insufficient on their own.
GLP-1 medicines plausibly influence appetite and some reward-related processes involved in eating. The 2026 meta-analysis provides an average signal of reduced binge-related scores. Yet that signal comes largely from populations without a confirmed BED diagnosis, while the small randomized BED pilot did not establish a significant between-group difference in binge reduction. Longer, larger BED-specific trials are required.
The American Psychiatric Association's 2023 practice guideline and NICE guideline NG69 describe established approaches that include eating-disorder-focused psychotherapy and guided self-help for appropriately selected patients. NICE cautions against using medication as the sole treatment for BED. In the United States, lisdexamfetamine has a specific FDA indication for moderate to severe BED in adults, with its own contraindications and monitoring considerations. That approval does not extend to GLP-1 medicines as a psychiatric BED treatment.
For the diagnosis-specific clinical picture, read Binge Eating Disorder: Symptoms, Diagnosis, and Treatment. For established and investigational medication options across disorders, see Medications for Eating Disorders: What Evidence Supports.
Could GLP-1 Medications Cause or Worsen an Eating Disorder?
There are plausible reasons to investigate harm: strong appetite suppression, persistent nausea, interference with nutritional intake, and the possibility that weight-focused treatment may interact with preexisting restrictive beliefs. A 2026 Journal of Psychiatric Research review describes emerging concerns alongside possible improvements in binge-eating outcomes.
The central uncertainty is causal. Reports of restriction appearing during medication exposure do not by themselves establish that a drug caused an eating disorder. Existing research cannot reliably quantify new eating-disorder incidence attributed to the medication or identify definitive risk estimates across diagnostic groups. Clinical vigilance is warranted while prospective comparative studies are developed.
Assessment should consider symptoms present before treatment, the reason for the prescription, concurrent psychological and social pressures, weight trajectory, nutritional status, and emerging behaviors. A patient can be concerned about side effects without having a psychiatric eating disorder, and a patient can have an eating disorder that is inadequately recognized because attention focuses on metabolic treatment.
A risk-aware approach creates room for both legitimate metabolic care and timely intervention when restrictive or compensatory symptoms emerge.
Risks by Eating Disorder Diagnosis
Anorexia nervosa
Anorexia nervosa involves persistent restriction and characteristic concerns or disturbances involving weight and shape. Undernutrition can affect cardiovascular, endocrine, skeletal, cognitive, and other bodily systems. A medicine that further suppresses appetite or causes nausea may complicate nutrition restoration. The September 2026 consensus recommends generally avoiding GLP-1 medications in active anorexia, especially where restraint and weight suppression are significant.
Atypical anorexia nervosa
Atypical anorexia is classified within other specified feeding or eating disorder (OSFED). It involves the essential features of anorexia nervosa despite weight remaining at or above a conventionally expected range after significant weight loss. It can produce substantial medical compromise. The Society for Adolescent Health and Medicine emphasizes growth history, magnitude and pace of weight change, and signs of physiological instability rather than BMI alone.
A person with atypical anorexia may be overlooked because of a larger body size. Medication-related appetite suppression in such a context requires careful medical and psychiatric assessment.
Bulimia nervosa
Bulimia nervosa features recurrent binge eating and inappropriate compensatory behavior. Reducing hunger does not necessarily eliminate compensatory behavior, shame, or overvaluation of body shape and weight. Vomiting and other compensatory behaviors may contribute to dehydration and electrolyte abnormalities, while drug-related gastrointestinal effects can complicate the clinical picture. Direct GLP-1 efficacy evidence for bulimia is inadequate. See Bulimia Nervosa: Symptoms, Diagnosis, and Treatment.
Binge eating disorder
BED is the best-studied potential eating-disorder indication for GLP-1 drugs, but the evidence remains preliminary. Restrictive patterns can coexist with BED, and monitoring should cover nutritional adequacy and distress as well as binge episodes. A reduction in body weight or reported binge frequency alone does not establish recovery.
Avoidant/restrictive food intake disorder
Avoidant/restrictive food intake disorder (ARFID) can involve sensory sensitivities, low interest in eating, or fear of aversive consequences such as choking or vomiting, without anorexia's central weight/shape concerns. Loss of appetite and gastrointestinal adverse effects could intensify difficulties meeting nutritional needs, although direct research on GLP-1 exposure in diagnosed ARFID is limited. Differential assessment should also consider underlying gastrointestinal illness, swallowing problems, and medication intolerance.
OSFED, UFED, purging disorder, and other conditions
Other specified feeding or eating disorder includes atypical anorexia and other clinically significant specified presentations. Unspecified feeding or eating disorder (UFED) is used when the clinician does not specify a reason that full criteria are unmet or available information is inadequate. Neither necessarily implies low risk. Purging disorder requires attention to the pattern and medical consequences of compensatory behavior.
Pica and rumination disorder are distinct feeding or eating diagnoses with different defining behaviors and medical differentials. Orthorexia is a popular and research term for a potentially impairing preoccupation with “healthy” eating; it is not a distinct DSM-5-TR diagnosis. GLP-1-specific treatment studies are not established for these conditions. Clinical evaluation should identify the actual presentation rather than generalize from BED studies.
Nutritional and Medical Safety Concerns
Inadequate intake and dehydration
Appetite suppression may make it harder for some patients to eat or drink adequately, especially when a restrictive pattern is already present. Persistent nausea, vomiting, diarrhea, or constipation may compound functional difficulty. Dehydration can affect kidney function, while prolonged poor intake raises concerns about nutritional deficiency and physical instability.
Electrolytes, circulation, and the heart
Eating disorders can be associated with abnormal pulse, blood pressure changes, fainting, and electrolyte disturbances. Clinical assessment may include vital signs, orthostatic measures, laboratory tests, and an electrocardiogram when indicated. The NICE recommendations specifically recognize the need for medical assessment and warn against determining treatment need from BMI alone.
A change in nutritional status may be clinically serious without a person reaching a conventionally low BMI. In adolescents, disrupted growth may add further risk. Medication-related vomiting should not automatically be dismissed as an expected side effect when dehydration, restriction, or a possible eating-disorder complication is also present.
Other drug adverse effects and contraindications
Depending on the product, prescribing information contains warnings and precautions involving pancreatitis, gallbladder disease, gastrointestinal intolerance, kidney injury associated with volume depletion, and hypoglycemia with certain concomitant diabetes drugs. Pregnancy-related labeling and individual contraindications also vary. Clinicians must consult the label for the actual product and indication.
The FDA warns about unapproved and compounded GLP-1 products, including quality and medication-error concerns. A drug's regulatory approval for a metabolic indication is not evidence that it has passed psychiatric eating-disorder efficacy trials.
Refeeding and nutritional rehabilitation
Substantial undernutrition can make nutritional restoration medically complex, including clinically significant fluid or electrolyte changes that may require supervision. A clinician-led eating-disorder team should manage nutritional rehabilitation when such risks exist. GLP-1-associated appetite suppression may interfere with an existing care plan, but no general self-directed refeeding strategy is appropriate for patients with medical instability.
Psychological Effects and the Meaning of Recovery
Patients may describe profound relief from food-related preoccupation. That experience deserves recognition and respectful exploration. Its clinical value depends on how it relates to nutritional stability, reduced distress, flexibility around eating, fewer clinically significant episodes, and improved quality of life.
A person can experience quieter hunger signals while remaining fearful of eating, distressed by body changes, or dependent on rigid food rules. A different person may experience fewer binge episodes and greater emotional flexibility. These possibilities illustrate why drug response should be evaluated as a set of physical and psychological outcomes rather than as a single weight or appetite metric.
Weight and appetite may change after discontinuation. The STEP 1 semaglutide trial extension documented weight regain following discontinuation in participants treated for obesity. That study did not investigate eating-disorder relapse or prove psychiatric effects of stopping the drug. Patients with established eating-disorder concerns may benefit from planned medical and psychological follow-up when a prescription changes.
Questions about body dissatisfaction, pressure to be thin, stigma, or social comparison are important contextual factors. The related Social Media and Body Image article addresses broader appearance-related psychology; the present article focuses on drug exposure and eating-disorder care.
What About Depression and Suicidal Thoughts?
On January 13, 2026, the U.S. Food and Drug Administration announced that its review had not found an increased risk of suicidal ideation or behavior associated with GLP-1 receptor agonists, and requested removal of relevant warning language for specific products. This is a significant regulatory finding that should be reported accurately.
It does not mean that depression, suicidal thoughts, or other psychiatric changes should be ignored in someone with an eating disorder. Those symptoms require independent evaluation according to their severity, regardless of medication exposure. Immediate self-harm danger requires emergency assistance.
Screening Before Starting Treatment
The 2026 Delphi consensus recommends assessment for current and past eating disorders before beginning GLP-1 treatment, including brief validated screening when appropriate. The conversation can cover previous diagnosis, dietary restriction, episodes of loss of control, compensatory behavior, weight/shape-related distress, significant weight suppression, and past treatment.
A positive screening result signals the need for further evaluation; a negative result cannot conclusively rule out an eating disorder. The NICE guideline cautions against using a screening questionnaire such as SCOFF as the sole basis for diagnosis. Interview findings, medical history, developmental context, and physical health all matter.
Prescribers should also consider the actual metabolic indication, comorbid illnesses such as diabetes, concurrent medication, gastrointestinal symptoms, nutritional stability, age, reproductive health, and accessibility of specialist follow-up. Screening should support care rather than create automatic exclusion based on stigma or appearance.
Monitoring During Treatment and After It Ends
Appropriate monitoring addresses both benefits and potential harm. Clinicians may ask whether the person can meet nutritional needs, whether restrictive rules have become more rigid, whether loss-of-control or compensatory behaviors have changed, and whether physical symptoms interfere with functioning. Relevant medical findings may include hydration, recent weight trajectory in its clinical context, vital signs, and selected tests when warranted.
The consensus panel supported monitoring during treatment and after discontinuation, with intensity based on existing and emerging risk. A review should distinguish anticipated pharmacological appetite effects from an increase in eating-disorder psychopathology. Those two processes can occur simultaneously.
If significant symptoms emerge, the prescribing clinician and eating-disorder specialist should review the medication's indication, medical stability, nutritional adequacy, psychological treatment needs, and whether continuation remains appropriate. Patients should discuss medication changes with their clinicians rather than independently altering a prescription that may also control diabetes or another condition.
Clinical Assessment and Differential Diagnosis
A full assessment establishes which symptoms were present before medication began, their timing and course, the motivations underlying eating behavior, and their consequences. It distinguishes nausea or reduced appetite from enduring restrictive beliefs, binge eating from normal variations in hunger, and medication-related gastrointestinal symptoms from rumination disorder, swallowing difficulties, or other medical conditions.
Binge eating is evaluated through the experience of loss of control, episode characteristics, associated distress, and functional consequences. Anorexia and atypical anorexia require careful assessment of restriction, characteristic psychological features, weight history, and physiological risk. ARFID requires assessment of avoidance motivations, nutrition, medical history, and developmental context.
Medical care can include examination, laboratory work, and other investigations according to symptoms. The APA practice guideline and SAHM position paper support integrated psychiatric, nutritional, and medical care for relevant eating-disorder presentations.
Evidence-Based Eating Disorder Treatment and GLP-1 Prescribing
A diagnosed eating disorder requires treatment appropriate to its diagnosis and severity. Depending on the clinical situation, care may include eating-disorder-focused cognitive behavioral interventions, guided self-help for selected BED presentations, family-based treatment for adolescents, nutritional restoration, medical stabilization, and diagnosis-specific pharmacotherapy. These pathways have their own evidence and are described in Eating Disorder Treatment: Evidence-Based Therapies and Care.
When a GLP-1 medication is considered for a recognized metabolic indication in someone with eating-disorder symptoms, coordination among prescriber, primary care clinician, eating-disorder specialist, and dietitian can address both conditions. Mental health treatment should not be displaced simply because appetite or weight has changed.
The September 2026 consensus generally favors avoidance in active anorexia, atypical anorexia, or bulimia with marked restraint. It also calls for individualized decisions in patients with past eating-disorder histories or other medical indications. For BED, emerging efficacy research warrants careful exploration while established interventions remain available.
Adolescents, Diabetes, Pregnancy, and Equity
Children and adolescents require attention to growth, pubertal development, nutrition, and family circumstances. A product's age-based regulatory indication for a metabolic condition does not establish safety or efficacy for treating an eating disorder. Research directly measuring GLP-1-associated psychiatric eating-disorder outcomes in young people remains limited.
People taking these drugs for type 2 diabetes may have meaningful metabolic benefits and additional medication interactions. A discontinuation decision can affect blood-glucose management, so risks must be balanced within a coordinated medical plan. In pregnancy, pregnancy planning, and breastfeeding, product-specific labeling and clinician guidance are essential, especially where nutritional vulnerabilities coexist.
Eating disorders affect people across body sizes, gender groups, and backgrounds. Some individuals with atypical anorexia or bulimia are underrecognized when care focuses predominantly on BMI. Others may experience barriers to metabolic care because of a psychiatric history. Equity requires assessment of actual symptoms, physical needs, and treatment access rather than assumptions based on appearance.
When to Seek Help
Contact the prescribing clinician or eating-disorder care team promptly if food or fluid intake is persistently inadequate, vomiting recurs, dizziness worsens, rigid restriction intensifies, or binge eating and compensatory behaviors change in concerning ways. Significant distress around eating or recurrence of symptoms after past recovery also deserves assessment.
Fainting, chest pain, irregular heartbeat, confusion, severe weakness, serious dehydration, or severe persistent abdominal pain may indicate medical instability and warrant urgent assessment. Immediate danger from suicidal thoughts calls for emergency help. Serious complications may occur at any body weight.
For further discussion of urgent assessment, read When Is an Eating Disorder a Medical Emergency? Warning Signs.
Research Gaps and Future Directions
The most important unresolved questions concern who might benefit, who may be harmed, and how benefits persist. Future research needs large randomized trials in people with clinician-confirmed BED, standardized outcomes for psychological recovery, longer follow-up, and direct comparisons with established treatment. Investigators should measure adverse restrictive patterns and nutritional status, not only weight and appetite.
Prospective studies also need to determine whether GLP-1 exposure increases, decreases, or leaves unchanged the incidence or recurrence of anorexia, atypical anorexia, bulimia, and other eating disorders. Appropriate controls must account for the medical indication, prior psychiatric history, and other factors that influence prescribing.
More research is needed in adolescents, underrepresented populations, those with diabetes and coexisting eating disorders, and patients who interrupt or discontinue medication. Consistent definitions of binge episodes, restraint, distress, and “food noise” will help prevent overgeneralization from one questionnaire score to a clinical diagnosis.
The present evidence supports careful screening, appropriate specialist care, and informed monitoring. It also supports continued investigation of GLP-1 medicines for BED. It does not support presenting appetite suppression as a complete eating-disorder treatment.
Frequently Asked Questions
Are Ozempic or Wegovy approved to treat binge eating disorder?
No. Their regulatory indications concern specified metabolic or weight-management conditions, not BED as a psychiatric diagnosis. Off-label use is a separate clinical decision requiring individual assessment.
Does semaglutide stop binge eating?
Some studies show reductions in binge-eating-related scores, but the evidence is not sufficient to promise remission. Larger trials in diagnosed BED populations are required.
Can GLP-1 medicines cause anorexia nervosa?
There are plausible concerns and emerging reports of restrictive symptoms, but current evidence cannot reliably establish the incidence or causation of newly diagnosed anorexia from GLP-1 treatment. Screening and monitoring remain prudent.
What happens if someone already has anorexia or atypical anorexia?
The September 2026 expert consensus recommends generally avoiding these medications in active restrictive illness, especially where restraint and weight suppression are significant. A separate metabolic indication requires individualized specialist review.
Are GLP-1 medications safe for someone with bulimia nervosa?
Direct evidence is limited. Restriction, gastrointestinal symptoms, dehydration, and electrolyte disturbances can create additional concerns. A prescribing clinician and eating-disorder specialist should assess the individual.
What about ARFID?
Direct clinical research is scarce. Loss of appetite and gastrointestinal symptoms may be particularly relevant to a person whose intake is already restricted by sensory sensitivities, low interest, or food-related fears.
Does weight loss mean BED has improved?
No. Clinicians assess episodes with loss of control, distress, function, and other psychopathology. Weight change is a separate medical outcome.
What is “food noise”?
It is an informal description of persistent or intrusive food-related thoughts. It is not itself a psychiatric diagnosis or a standardized outcome across GLP-1 trials.
Can a screening questionnaire diagnose an eating disorder?
No. Screening can identify people who need further evaluation. Diagnosis requires a qualified clinical assessment and, when indicated, medical evaluation.
Should someone with a past eating disorder avoid GLP-1 drugs forever?
A past diagnosis deserves careful review, especially after a restrictive disorder, but it is not a complete prescribing decision by itself. Current symptoms, medical indication, nutritional and psychological stability, and clinical support matter.
What happens after a GLP-1 medicine is stopped?
Appetite, weight, and metabolic outcomes may change. The STEP 1 extension showed weight regain after semaglutide withdrawal, but it did not investigate eating-disorder relapse.
Does the FDA believe GLP-1 drugs cause suicidal thoughts?
In January 2026 the FDA announced that its review found no increased risk and requested removal of related label warnings from relevant products. Individual mental health symptoms still require evaluation.
What if an eating disorder seems worse during treatment?
Contact the prescriber and an eating-disorder specialist promptly. They can evaluate physical safety and treatment options while considering the medication's legitimate medical indication.
Related Articles
References
Allison, K. C., et al. (2023). A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder. Obesity Science & Practice, 9(2), 127–136. https://doi.org/10.1002/osp4.619
American Psychiatric Association. (2023). The practice guideline for the treatment of patients with eating disorders, fourth edition. https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines/eating-disorders
Emptage, I., et al. (2026). The effectiveness of glucagon-like peptide-1 receptor agonists on binge eating in patients with obesity: A systematic review and meta-analysis. eClinicalMedicine, 98, 104007. https://doi.org/10.1016/j.eclinm.2026.104007
Jebeile, H., et al. (2026). GLP-1 receptor agonist medications for obesity and type 2 diabetes treatment: A rapid review of changes in eating behaviors and eating disorder risk. Obesity Reviews, 27(4), e70049. https://doi.org/10.1111/obr.70049
Keshen, A., et al. (2026). Consensus-based clinical and research recommendations for use of glucagon-like peptide-1 receptor agonists in the context of eating disorders: A modified Delphi study. World Psychiatry, 25(3), 465–474. https://doi.org/10.1002/wps.70096
Leziak, A., Kochman, K., & Kocełak, P. (2026). The dual role of GLP-1 receptor agonists in weight management and eating disorders: Potential benefits and risks. Journal of Psychiatric Research, 197, 243–249. https://doi.org/10.1016/j.jpsychires.2026.03.008
National Institute for Health and Care Excellence. (2017; updated). Eating disorders: Recognition and treatment (NG69). https://www.nice.org.uk/guidance/ng69/chapter/recommendations
National Institute of Mental Health. (n.d.). Eating disorders: What you need to know. https://www.nimh.nih.gov/health/publications/eating-disorders
Richards, J., et al. (2023). Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study. Obesity Pillars, 7, 100080. https://doi.org/10.1016/j.obpill.2023.100080
Society for Adolescent Health and Medicine. (2022). Medical management of restrictive eating disorders in adolescents and young adults. Journal of Adolescent Health, 71(5), 648–654. https://doi.org/10.1016/j.jadohealth.2022.08.006
U.S. Food and Drug Administration. (2026a). FDA requests removal of suicidal behavior and ideation warning from GLP-1 RA medications. https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp
U.S. Food and Drug Administration. (2026b). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
Wilding, J. P. H., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725
World Health Organization. (2025). Obesity: GLP-1 therapies. https://www.who.int/news-room/questions-and-answers/item/obesity-glp-1-therapies